Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-06-16

AUTHORS

E. Jason Abel, Christopher G. Wood

ABSTRACT

The development of targeted therapy for renal cell carcinoma (RCC) has changed the treatment options for patients with metastatic RCC. The authors of this Review discuss the current and future role of cytoreductive nephrectomy in combination with targeted therapies, and the rationale for presurgical therapy for this group of patients.

PAGES

375-383

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/nrurol.2009.102

DOI

http://dx.doi.org/10.1038/nrurol.2009.102

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050033113

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19528960


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzenesulfonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Delivery Systems", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nephrectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sorafenib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abel", 
        "givenName": "E. Jason", 
        "id": "sg:person.015655227237.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015655227237.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1479-5876-5-32", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001875982", 
          "https://doi.org/10.1186/1479-5876-5-32"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-06-16", 
    "datePublishedReg": "2009-06-16", 
    "description": "The development of targeted therapy for renal cell carcinoma (RCC) has changed the treatment options for patients with metastatic RCC. The authors of this Review discuss the current and future role of cytoreductive nephrectomy in combination with targeted therapies, and the rationale for presurgical therapy for this group of patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/nrurol.2009.102", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1034152", 
        "issn": [
          "1759-4812", 
          "1759-4820"
        ], 
        "name": "Nature Reviews Urology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "renal cell carcinoma", 
      "metastatic renal cell carcinoma", 
      "cytoreductive nephrectomy", 
      "group of patients", 
      "presurgical therapy", 
      "cell carcinoma", 
      "treatment options", 
      "targeted therapy", 
      "therapy", 
      "nephrectomy", 
      "patients", 
      "carcinoma", 
      "future role", 
      "review", 
      "group", 
      "options", 
      "rationale", 
      "role", 
      "combination", 
      "development", 
      "authors", 
      "era"
    ], 
    "name": "Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy", 
    "pagination": "375-383", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050033113"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/nrurol.2009.102"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19528960"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/nrurol.2009.102", 
      "https://app.dimensions.ai/details/publication/pub.1050033113"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_489.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/nrurol.2009.102"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2009.102'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2009.102'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2009.102'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrurol.2009.102'


 

This table displays all metadata directly associated to this object as RDF triples.

158 TRIPLES      21 PREDICATES      64 URIs      55 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/nrurol.2009.102 schema:about N28c4cf8f4293464fb6c4860106d78cae
2 N370faec617b9471ca7ef375f9491c876
3 N6a4ee03f522847faa9bdb7d6240760bf
4 N6bf63cb250aa488cba93b84ed7ea1626
5 N7660f18ee6df49d891b1606e823d81ad
6 N806702bf3ea04ae4b580875375c692a9
7 N8208261e2b7742b2b25cbff2efca7b40
8 N9ea3accf39d6406aaa69fbcfb958965c
9 Nad61c6b24ee04b5da284d0ba89114ebf
10 Naf000d63aa6548e484cf818078959a17
11 Nc5cce49de6ff4d37a4c320e00c0e418c
12 Nc74f57960f4b469fbea40160b0ac39c6
13 Ncdf5f2e2459b4db89a9e2e5784f6a565
14 Ndcb6c8ed796d4819a213b2b9369a9d8e
15 Neb5d0b732f73412d83265947bf132a4b
16 Necd4d8100cda48e69e898f589298f202
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N84284a4cdeb14d9aa01e15acc4331b09
20 schema:citation sg:pub.10.1186/1479-5876-5-32
21 schema:datePublished 2009-06-16
22 schema:datePublishedReg 2009-06-16
23 schema:description The development of targeted therapy for renal cell carcinoma (RCC) has changed the treatment options for patients with metastatic RCC. The authors of this Review discuss the current and future role of cytoreductive nephrectomy in combination with targeted therapies, and the rationale for presurgical therapy for this group of patients.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf N359acfc031984a17b8b105a72853cea8
27 Ncb64f49757a6444fa8c516fa27a9edf2
28 sg:journal.1034152
29 schema:keywords authors
30 carcinoma
31 cell carcinoma
32 combination
33 cytoreductive nephrectomy
34 development
35 era
36 future role
37 group
38 group of patients
39 metastatic renal cell carcinoma
40 nephrectomy
41 options
42 patients
43 presurgical therapy
44 rationale
45 renal cell carcinoma
46 review
47 role
48 targeted therapy
49 therapy
50 treatment options
51 schema:name Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy
52 schema:pagination 375-383
53 schema:productId N020d734dcbbf466db859dd82cb0d764b
54 N4f94193bc953409a8e5217662d23f615
55 Nde3a527c289f4a08ba992188bef3a0bf
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050033113
57 https://doi.org/10.1038/nrurol.2009.102
58 schema:sdDatePublished 2022-10-01T06:35
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N6f3c445d6d6d4e9e989918f442b6ff22
61 schema:url https://doi.org/10.1038/nrurol.2009.102
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N020d734dcbbf466db859dd82cb0d764b schema:name doi
66 schema:value 10.1038/nrurol.2009.102
67 rdf:type schema:PropertyValue
68 N28c4cf8f4293464fb6c4860106d78cae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Kidney Neoplasms
70 rdf:type schema:DefinedTerm
71 N359acfc031984a17b8b105a72853cea8 schema:volumeNumber 6
72 rdf:type schema:PublicationVolume
73 N370faec617b9471ca7ef375f9491c876 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Sorafenib
75 rdf:type schema:DefinedTerm
76 N4f94193bc953409a8e5217662d23f615 schema:name pubmed_id
77 schema:value 19528960
78 rdf:type schema:PropertyValue
79 N639dbfd041aa4f27add603cbc98c601e rdf:first sg:person.01040121722.56
80 rdf:rest rdf:nil
81 N6a4ee03f522847faa9bdb7d6240760bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Antineoplastic Agents
83 rdf:type schema:DefinedTerm
84 N6bf63cb250aa488cba93b84ed7ea1626 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Sunitinib
86 rdf:type schema:DefinedTerm
87 N6f3c445d6d6d4e9e989918f442b6ff22 schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 N7660f18ee6df49d891b1606e823d81ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Pyrroles
91 rdf:type schema:DefinedTerm
92 N806702bf3ea04ae4b580875375c692a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Carcinoma, Renal Cell
94 rdf:type schema:DefinedTerm
95 N8208261e2b7742b2b25cbff2efca7b40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Pyridines
97 rdf:type schema:DefinedTerm
98 N84284a4cdeb14d9aa01e15acc4331b09 rdf:first sg:person.015655227237.00
99 rdf:rest N639dbfd041aa4f27add603cbc98c601e
100 N9ea3accf39d6406aaa69fbcfb958965c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Niacinamide
102 rdf:type schema:DefinedTerm
103 Nad61c6b24ee04b5da284d0ba89114ebf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Combined Modality Therapy
105 rdf:type schema:DefinedTerm
106 Naf000d63aa6548e484cf818078959a17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Drug Delivery Systems
108 rdf:type schema:DefinedTerm
109 Nc5cce49de6ff4d37a4c320e00c0e418c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Benzenesulfonates
111 rdf:type schema:DefinedTerm
112 Nc74f57960f4b469fbea40160b0ac39c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Phenylurea Compounds
114 rdf:type schema:DefinedTerm
115 Ncb64f49757a6444fa8c516fa27a9edf2 schema:issueNumber 7
116 rdf:type schema:PublicationIssue
117 Ncdf5f2e2459b4db89a9e2e5784f6a565 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Nephrectomy
119 rdf:type schema:DefinedTerm
120 Ndcb6c8ed796d4819a213b2b9369a9d8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Indoles
122 rdf:type schema:DefinedTerm
123 Nde3a527c289f4a08ba992188bef3a0bf schema:name dimensions_id
124 schema:value pub.1050033113
125 rdf:type schema:PropertyValue
126 Neb5d0b732f73412d83265947bf132a4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Randomized Controlled Trials as Topic
128 rdf:type schema:DefinedTerm
129 Necd4d8100cda48e69e898f589298f202 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Humans
131 rdf:type schema:DefinedTerm
132 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
133 schema:name Medical and Health Sciences
134 rdf:type schema:DefinedTerm
135 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
136 schema:name Oncology and Carcinogenesis
137 rdf:type schema:DefinedTerm
138 sg:journal.1034152 schema:issn 1759-4812
139 1759-4820
140 schema:name Nature Reviews Urology
141 schema:publisher Springer Nature
142 rdf:type schema:Periodical
143 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
144 schema:familyName Wood
145 schema:givenName Christopher G.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
147 rdf:type schema:Person
148 sg:person.015655227237.00 schema:affiliation grid-institutes:grid.240145.6
149 schema:familyName Abel
150 schema:givenName E. Jason
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015655227237.00
152 rdf:type schema:Person
153 sg:pub.10.1186/1479-5876-5-32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001875982
154 https://doi.org/10.1186/1479-5876-5-32
155 rdf:type schema:CreativeWork
156 grid-institutes:grid.240145.6 schema:alternateName Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
157 schema:name Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
158 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...